China SXT Pharmaceuticals Income Statement 2026-2011 | SXTC

Brief overview of financial results at China SXT Pharmaceuticals

This overview is based on financial performance over the past five years. China SXT Pharmaceuticals reported revenue of 5.2 million dollars in 2020 and 1.7 million dollars by 2025. Overall revenue changed by −66.3%, equal to an annualized rate of about −19.5%. The business finished the period with a smaller revenue base.

At the gross-profit level, the result moved from 2.7 million dollars to 367 thousand dollars, a change of −86.4%. The relationship between sales and direct costs deteriorated. The gross margin was 52.4% at the start and 21.1% at the end. The margin decline reflects a less favorable sales-and-cost structure.

Over the period, EBITDA shifted from −1 million dollars to −2.6 million dollars, a change of −157.4%. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was −19.6% at the start and −149.2% at the end. Cost pressure reduced operating profitability.

Comparing the endpoints shows a move from −10.3 million dollars to −3.3 million dollars. The direction improved, yet positive earnings are still absent.

The market value of the business moved from 407 thousand dollars to 2.3 million dollars, or +456.3%. A large part of future progress may already be reflected in the valuation.

Conclusion

The indicators point to a weaker financial profile. The constructive conclusion rests on net-income growth. Caution is warranted because of weaker operating efficiency, a low EBITDA margin and a lower gross margin. The key question is whether sales can be converted into sustainable profit.